Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine

Next Previous
Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms RELIEF
  • Sponsors Lundbeck A/S

Most Recent Events

  • 12 Jun 2022 Results of post-hoc analysis optimization of acute treatment and headache- related impact following eptinezumab initiated during a migraine attack, presented at the 64th Annual Scientific Meeting of the American Headache Society.
  • 09 Jun 2022 According to a Lundbeck A/S media release, a post-hoc analysis of this study will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS), 2022.
  • 26 Apr 2022 Results of post hoc analysis from this study assessing optimization of acute treatment and headache-related impact following eptinezumab treatment presented at the 74th Annual Meeting of the American Academy of Neurology 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top